Dualyx aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company is developing the pipeline together with our academic and industry partners such as Wurzburg University, argenx, KU Leuven and VIB.
Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Graefelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle/Saale, Germany, and Melbourne, Australia.
Immunic is developing three small molecule products: lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis, ulcerative colitis and, in collaboration with the Mayo Clinic, primary sclerosing cholangitis.
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary microbiome profiling technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®.
Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases for which there are currently no satisfactory therapies and which lead to high mortality or poor quality of life. Examples include septic shock, acute GvHD and the lung disease BPD.
The mission of MDTB Cell Manufacturing GmbH is the industrial-pharmaceutical production of MSC-based drugs in Germany as clinically well manageable Advanced Therapy Medical Products (off-the-shelf/ready-to-use) to significantly improve the health of affected patients. The manufacturing costs and the progress made in scaling up should also enable application in large patient groups.
Desacell® is currently being tested internationally in several clinical studies.
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.
